Skip to main content
Erschienen in: Supportive Care in Cancer 7/2008

01.07.2008 | Supportive Care International

Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway

verfasst von: Silje Engdal, Aslak Steinsbekk, Olbjørn Klepp, Odd Georg Nilsen

Erschienen in: Supportive Care in Cancer | Ausgabe 7/2008

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

This survey aims to explore the differences between cancer patients undergoing chemotherapeutic treatment with palliative or curative intention with respect to concurrent herbal use, experiences of adverse effects, motives of herbal intake, and communication about herbal use with health care providers.

Materials and methods

One hundred and twelve adult cancer patients from the west coast of Central Norway, currently undergoing chemotherapeutic treatment, were recruited to a cross-sectional descriptive survey.

Main results

Palliative and curative patients used herbal remedies concurrent with chemotherapy equally frequent (37% and 38%). One palliative patient reported adverse effects when doubling the dose of injected mistletoe used. Garlic was only used by palliative patients (p = 0.009) who also tended to have a more frequent everyday herbal use (78% vs 67%, respectively) than curative patients (p = 0.075). Curative patients, however, used herbal remedies more often to counteract adverse reactions (31% vs 3%, respectively; p = 0.026). A bivariate logistic regression, which was adjusted for age, showed that palliative patients used herbal remedies more frequently to improve their immune system (adjusted OR = 7.5, 95% CI = 1.1–49.7).

Conclusions

This is the first survey comparing concurrent herbal use between cancer patients undergoing palliative or curative chemotherapy. Both groups frequently use herbal remedies concurrent with chemotherapy, but with a slightly different intent. The frequent concurrent use emphasizes the need for clinicians to include questions on complementary and alternative medicine in routine history taking and for further studies on possible herb–drug interactions among the cancer patient.
Literatur
1.
Zurück zum Zitat Boon HS, Olatunde F, Zick SM (2007) Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health 7:4PubMedCrossRef Boon HS, Olatunde F, Zick SM (2007) Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health 7:4PubMedCrossRef
2.
Zurück zum Zitat Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van RM, Kessler RC (1998) Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280:1569–1575PubMedCrossRef Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van RM, Kessler RC (1998) Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280:1569–1575PubMedCrossRef
3.
Zurück zum Zitat Ernst E, Cassileth BR (1998) The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 83:777–782PubMedCrossRef Ernst E, Cassileth BR (1998) The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 83:777–782PubMedCrossRef
4.
Zurück zum Zitat Giveon SM, Liberman N, Klang S, Kahan E (2003) A survey of primary care physicians’ perceptions of their patients’ use of complementary medicine. Complement Ther Med 11:254–260PubMedCrossRef Giveon SM, Liberman N, Klang S, Kahan E (2003) A survey of primary care physicians’ perceptions of their patients’ use of complementary medicine. Complement Ther Med 11:254–260PubMedCrossRef
5.
Zurück zum Zitat Giveon SM, Liberman N, Klang S, Kahan E (2004) Are people who use “natural drugs” aware of their potentially harmful side effects and reporting to family physician. Patient Educ Couns 53:5–11PubMedCrossRef Giveon SM, Liberman N, Klang S, Kahan E (2004) Are people who use “natural drugs” aware of their potentially harmful side effects and reporting to family physician. Patient Educ Couns 53:5–11PubMedCrossRef
6.
Zurück zum Zitat Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC (2003) The interaction between St John’s wort and an oral contraceptive. Clin Pharmacol Ther 74:525–535PubMedCrossRef Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC (2003) The interaction between St John’s wort and an oral contraceptive. Clin Pharmacol Ther 74:525–535PubMedCrossRef
7.
Zurück zum Zitat Howat A, Veitch C, Cairns W (2006) A descriptive study comparing health attitudes of urban and rural oncology patients. Rural Remote Health 6:563PubMed Howat A, Veitch C, Cairns W (2006) A descriptive study comparing health attitudes of urban and rural oncology patients. Rural Remote Health 6:563PubMed
8.
Zurück zum Zitat Humpel N, Jones SC (2006) Gaining insight into the what, why and where of complementary and alternative medicine use by cancer patients and survivors. Eur J Cancer Care 15:362–368CrossRef Humpel N, Jones SC (2006) Gaining insight into the what, why and where of complementary and alternative medicine use by cancer patients and survivors. Eur J Cancer Care 15:362–368CrossRef
9.
Zurück zum Zitat Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, Nakano T, Takashima S (2005) Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol 23:2645–2654PubMedCrossRef Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, Nakano T, Takashima S (2005) Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol 23:2645–2654PubMedCrossRef
10.
Zurück zum Zitat Lee MM, Lin SS, Wrensch MR, Adler SR, Eisenberg D (2000) Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst 92:42–47PubMedCrossRef Lee MM, Lin SS, Wrensch MR, Adler SR, Eisenberg D (2000) Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst 92:42–47PubMedCrossRef
11.
Zurück zum Zitat Maher EJ, Mackenzie C, Young T, Marks D (1996) The use of the Hospital Anxiety and Depression Scale (HADS) and the EORTC QLQ-C30 questionnaires to screen for treatable unmet needs in patients attending routinely for radiotherapy. Cancer Treat Rev 22(Suppl A):123–129PubMedCrossRef Maher EJ, Mackenzie C, Young T, Marks D (1996) The use of the Hospital Anxiety and Depression Scale (HADS) and the EORTC QLQ-C30 questionnaires to screen for treatable unmet needs in patients attending routinely for radiotherapy. Cancer Treat Rev 22(Suppl A):123–129PubMedCrossRef
12.
Zurück zum Zitat McCune JS, Hatfield AJ, Blackburn AAR, Leith PO, Livingston RB, Ellis GK (2004) Potential of chemotherapy–herb interactions in adult cancer patients. Support Care Cancer 12:454–462PubMedCrossRef McCune JS, Hatfield AJ, Blackburn AAR, Leith PO, Livingston RB, Ellis GK (2004) Potential of chemotherapy–herb interactions in adult cancer patients. Support Care Cancer 12:454–462PubMedCrossRef
13.
Zurück zum Zitat Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AM, Platin N, Kearney N, Patiraki E (2005) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655–663PubMedCrossRef Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AM, Platin N, Kearney N, Patiraki E (2005) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655–663PubMedCrossRef
14.
Zurück zum Zitat Ohlen J, Balneaves LG, Bottorff JL, Brazier ASA (2006) The influence of significant others in complementary and alternative medicine decisions by cancer patients. Soc Sci Med 63:1625–1636PubMedCrossRef Ohlen J, Balneaves LG, Bottorff JL, Brazier ASA (2006) The influence of significant others in complementary and alternative medicine decisions by cancer patients. Soc Sci Med 63:1625–1636PubMedCrossRef
15.
Zurück zum Zitat Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505–2514PubMed Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505–2514PubMed
16.
Zurück zum Zitat Risberg T, Kolstad A, Bremnes Y, Holte H, Wist EA, Mella O, Klepp O, Wilsgaard T, Cassileth BR (2004) Knowledge of and attitudes toward complementary and alternative therapies: a national multicentre study of oncology professionals in Norway. Eur J Cancer 40:529–535PubMedCrossRef Risberg T, Kolstad A, Bremnes Y, Holte H, Wist EA, Mella O, Klepp O, Wilsgaard T, Cassileth BR (2004) Knowledge of and attitudes toward complementary and alternative therapies: a national multicentre study of oncology professionals in Norway. Eur J Cancer 40:529–535PubMedCrossRef
17.
Zurück zum Zitat Timmermans LM, van der Maazen RW, Leer JW, Kraaimaat FW (2006) Palliative or curative treatment intent affects communication in radiation therapy consultations. Psycho-oncology 15:713–725PubMedCrossRef Timmermans LM, van der Maazen RW, Leer JW, Kraaimaat FW (2006) Palliative or curative treatment intent affects communication in radiation therapy consultations. Psycho-oncology 15:713–725PubMedCrossRef
18.
Zurück zum Zitat Wilkinson S, Aldridge J, Salmon I, Cain E, Wilson B (1999) An evaluation of aromatherapy massage in palliative care. Palliat Med 13:409–417PubMedCrossRef Wilkinson S, Aldridge J, Salmon I, Cain E, Wilson B (1999) An evaluation of aromatherapy massage in palliative care. Palliat Med 13:409–417PubMedCrossRef
19.
Zurück zum Zitat World Health Organization (2005) National policy on traditional medicine and regulation of herbal medicines—report of a WHO global survey. World Health Organization, Geneva, p 1 World Health Organization (2005) National policy on traditional medicine and regulation of herbal medicines—report of a WHO global survey. World Health Organization, Geneva, p 1
20.
Zurück zum Zitat Yates JS, Mustian KM, Morrow GR, Gillies LJ, Padmanaban D, Atkins JN, Issell B, Kirshner JJ, Colman LK (2005) Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer 13:806–811PubMedCrossRef Yates JS, Mustian KM, Morrow GR, Gillies LJ, Padmanaban D, Atkins JN, Issell B, Kirshner JJ, Colman LK (2005) Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer 13:806–811PubMedCrossRef
Metadaten
Titel
Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway
verfasst von
Silje Engdal
Aslak Steinsbekk
Olbjørn Klepp
Odd Georg Nilsen
Publikationsdatum
01.07.2008
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 7/2008
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-007-0371-3

Weitere Artikel der Ausgabe 7/2008

Supportive Care in Cancer 7/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.